### ü´† Cardiomyopathy: Cardiac Amyloidosis Diagnosis

#### ‚úÖ True Statements
1. **99m‚ÄëTechnetium pyrophosphate (99mTc‚ÄëPYP) scintigraphy** is a diagnostic imaging test that specifically identifies **cardiac amyloidosis** caused by **transthyretin (ATTR) protein** deposition.
2. The two most common forms of **cardiac amyloidosis** are **amyloid light‚Äëchain (AL) amyloidosis**, in which amyloid fibrils consist of monoclonal immunoglobulin light chains, and **ATTR amyloidosis**, in which fibrils consist of transthyretin.
3. Echocardiographic findings that suggest **cardiac amyloidosis** include **increased left ventricular wall thickness**, **grade¬†2 or higher diastolic dysfunction**, and an **apical‚Äësparing global longitudinal strain pattern**.
4. On **electrocardiogram (ECG)**, **cardiac amyloidosis** may manifest as **low‚Äëvoltage QRS complexes** despite increased left ventricular wall thickness.
5. **Cardiac magnetic resonance (CMR) imaging** that demonstrates **diffuse late gadolinium enhancement** is highly suggestive of **cardiac amyloidosis** but cannot distinguish between AL and ATTR subtypes.
6. Evaluation for **AL amyloidosis** requires testing for a **monoclonal gammopathy** with **serum and urine immunofixation and free light‚Äëchain assay**.
7. **Cardiac amyloidosis** should be suspected when an echocardiogram shows **increased wall thickness** in conjunction with a **low‚Äëvoltage ECG**.
8. **Cardiac positron emission tomography (PET)** myocardial perfusion imaging is useful for assessing **coronary artery disease** but has **no role** in diagnosing **cardiac amyloidosis**.
9. **Stress echocardiography** is indicated for ischemia or hemodynamic assessment but is **not useful** for evaluating suspected **cardiac amyloidosis**.
10. **Transesophageal echocardiography (TEE)** is reserved for specific indications (such as infective endocarditis, prosthetic valve assessment, acute aortic pathology, or left atrial thrombus) and is **not indicated** for diagnosing **cardiac amyloidosis**.

#### üí¨ Extra
1. 99mTc‚ÄëPYP binds to myocardial ATTR amyloid deposits; positive cardiac uptake in the absence of a monoclonal protein essentially confirms ATTR cardiac amyloidosis.
2. Distinguishing AL from ATTR is crucial because AL amyloidosis requires prompt chemotherapy‚Äëbased treatment, whereas ATTR is managed with transthyretin stabilizers and gene‚Äësilencing therapies.
3. The ‚Äúapical‚Äësparing‚Äù strain pattern appears as relative preservation of longitudinal strain at the apex and correlates with amyloid infiltration of the basal and mid‚Äësegments.
4. Low‚Äëvoltage ECG despite ventricular wall thickening reflects electrical dampening by interstitial amyloid deposition.
5. CMR findings support the diagnosis when echocardiography is equivocal, but tissue characterization cannot specify the amyloid subtype.
6. Identifying a monoclonal gammopathy differentiates AL from ATTR and guides subsequent hematologic evaluation.
8. PET tracers do not bind amyloid fibrils; therefore, PET perfusion imaging cannot detect amyloid infiltration.
9. Stress echocardiography does not improve diagnostic yield for amyloidosis and exposes the patient to unnecessary testing in this context.
10. TEE offers no additional information about myocardial infiltration and carries procedural risks not justified for suspected amyloidosis alone.

#### üî∑ Tags
#Cardiology #HospitalCare #CardiacAmyloidosis #Cardiomyopathy #ATTR #AL #Imaging #Scintigraphy #Echocardiography

#### üìô Reference
Kittleson MM, Ruberg FL, Ambardekar AV, et¬†al; Writing Committee. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. *Journal of the American College of Cardiology*. 2023;81:1076‚Äë1126. PMID:¬†36697326 doi:10.1016/j.jacc.2022.11.022

#### üÜî Question ID
CVMCQ24026

#### üïí Last Updated
February¬†2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Diagnostic Testing in Cardiology, Diagnostic Testing for Structural Heart Disease

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Diagnostic testing for structural heart disease should be considered in patients with a suggestive history and physical examination findings, such as **heart failure symptoms**, **grade 3/6 or louder systolic murmurs**, **diastolic or continuous murmurs**, or murmurs associated with **exertional dyspnea, light-headedness, or chest pain**.
2. Repeat cardiac imaging is indicated when there is a **change in clinical presentation**, **functional status**, or **examination findings** in patients with known structural heart disease.
3. In congenital and valvular disease, the **frequency of surveillance imaging** is guided by **lesion severity**.
4. **Transthoracic echocardiography (TTE)** is the **mainstay noninvasive imaging modality** for structural heart disease.
5. TTE evaluates **right and left ventricular chamber size**, **wall thickness**, **systolic function**, and **regional wall motion**.
6. TTE also provides information on **valvular pathology**, **diastolic function**, **hemodynamics**, and **pericardial effusion**.
7. **Intravenous agitated saline contrast** can be used with TTE to document the presence of an **intracardiac shunt**.
8. **Dobutamine stress echocardiography** can help distinguish **severe aortic stenosis** from **pseudo-severe aortic stenosis** in patients with **low-gradient AS and reduced ejection fraction**.
9. **Point-of-care ultrasound (POCUS)** can assess **gross cardiac function**, **chamber size**, **inferior vena cava size**, and **pericardial effusion**.
10. **Transesophageal echocardiography (TEE)** is commonly used to evaluate **infective endocarditis** and its complications, such as **abscess**.
11. TEE is useful for assessing **valvular pathology** before surgical or percutaneous interventions.
12. TEE is preferred in patients with **implanted devices** or **inconclusive TTE**.
13. TEE can detect **acute aortic abnormalities** and is used to **rule out left atrial thrombus** before **cardioversion**.
14. **Contraindications to TEE** include **esophageal strictures** and **active esophageal varices**.
15. **Esophageal injury**, including **perforation and bleeding**, is a rare complication of TEE.
16. **Cardiac magnetic resonance (CMR)** imaging can evaluate **myocardial and pericardial disease**, especially **inflammatory and infiltrative cardiomyopathies**.
17. CMR is particularly useful for **hypertrophic cardiomyopathy** with **eccentric or apical hypertrophy** not well seen on echocardiography.
18. CMR can serve as an **alternative to TEE** for assessing **valvular pathology** when **TTE is inadequate**.
19. TTE findings may raise suspicion for **cardiac amyloidosis**, but diagnosis requires **CMR or tissue biopsy**.
20. **99m-Technetium pyrophosphate (99mTc-PYP) scintigraphy** can differentiate **transthyretin (ATTR) amyloidosis** from other amyloid types.
21. 99mTc-PYP scintigraphy has **>99% specificity** for **ATTR cardiac amyloidosis**.
22. **Focused cardiac imaging with point-of-care ultrasound (POCUS)** is commonly used in emergency medicine to assess **volume status via inferior vena cava size**.
23. **Intravenous agitated saline** is **normally cleared by the pulmonary circulation** unless there is a **right-to-left intracardiac shunt**.
24. **TEE probe placement** occurs in the **distal esophagus and stomach**, providing proximity to posterior cardiac structures.
25. **CMR imaging** enables **three-dimensional reconstruction of cardiac anatomy** using **non-ionizing techniques**.
26. **99m-Technetium pyrophosphate (99mTc-PYP)** scintigraphy allows **visual comparison of cardiac versus bone radiotracer uptake**.

#### üí¨ Extra
1. Murmurs with concerning characteristics or symptoms increase the pretest probability for structural abnormalities.
2. A clinical change warrants imaging to reassess anatomy and function.
3. This is aligned with adult congenital and valvular disease guidelines.
4. TTE is often the first-line diagnostic test for suspected structural heart disease.
5. Chamber dimensions and wall thickness are essential parameters in cardiomyopathy evaluation.
6. TTE assesses pericardial space for effusion and valvular leaflets for regurgitation or stenosis.
7. Agitated saline contrast reveals right-to-left shunts when bubbles bypass pulmonary filtration.
8. Dobutamine improves contractility, aiding in identifying flow-limiting stenosis under stress.
9. POCUS is a rapid bedside screening tool in emergency or critical care settings.
10. TEE is more sensitive than TTE for small vegetations and paravalvular abscesses.
11. TEE offers better resolution for surgical planning.
12. Acoustic shadowing from devices (e.g., prosthetic valves) limits TTE utility.
13. Visualization of LAA is critical before restoring sinus rhythm (see Figure 1).
14. Sedation and probe passage can worsen preexisting esophageal pathology.
15. Although rare, serious complications from TEE must be considered in risk-benefit analysis.
16. CMR can differentiate myocarditis, sarcoidosis, amyloidosis, and pericardial constriction.
17. CMR offers superior apical resolution and detects variants not seen in standard echo windows.
18. CMR provides a noninvasive alternative when TEE is high risk or poorly tolerated.
19. Echocardiographic features of amyloidosis include thickened walls and granular appearance.
20. Differentiating AL from ATTR amyloidosis is critical because treatment strategies differ.
21. Bone tracer uptake by myocardium is characteristic of transthyretin amyloid infiltration (see Figure 2).
22. Inferior vena cava diameter collapsibility provides a bedside estimate of right atrial pressure or preload.
23. In a normal heart, microbubbles from agitated saline do not cross into the left heart due to pulmonary filtration.
24. This anatomic positioning allows TEE to image posterior valves (mitral, left atrial appendage) in high resolution.
25. This is valuable in structural heart disease where echocardiographic windows are limited or obstructed.
26. Cardiac uptake greater than bone uptake strongly supports transthyretin (ATTR) cardiac amyloidosis.

#### üè∑Ô∏è Tags
#Echocardiography #TTE #TEE #CMR #Amyloidosis #CardiacImaging #POCUS #99mTcPYP #HeartFailure #StructuralHeartDisease

---

### üßæ Supplemental Table

<table>
  <caption><strong>Diagnostic Testing for Structural Heart Disease</strong></caption>
  <thead>
    <tr>
      <th>Diagnostic Test</th>
      <th>Major Indications</th>
      <th>Advantages</th>
      <th>Limitations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Transthoracic echocardiography</td>
      <td>Heart failure, cardiomyopathy, valvular disease, congenital heart disease, pulmonary hypertension, aortic disease, pericardial disease</td>
      <td>Accurate diagnosis, quantification of LV size and function, portable and fast</td>
      <td>Operator-dependent, limited image quality in some patients, may require contrast</td>
    </tr>
    <tr>
      <td>Transesophageal echocardiography</td>
      <td>Endocarditis, prosthetic valve dysfunction, embolic source evaluation, aortic disease, left atrial thrombus</td>
      <td>High-resolution images of posterior structures, most accurate for thrombus and prosthetics</td>
      <td>Requires sedation and esophageal intubation</td>
    </tr>
    <tr>
      <td>Three-dimensional echocardiography</td>
      <td>Mitral valve disease, ASD closure, cardiac masses</td>
      <td>Improved tomographic and procedural imaging</td>
      <td>Limited by availability and expertise</td>
    </tr>
    <tr>
      <td>Radionuclide angiography (MUGA)</td>
      <td>Evaluation of LV systolic function</td>
      <td>Quantitative EF measurement, accurate for serial monitoring</td>
      <td>Radiation exposure, no structural data</td>
    </tr>
    <tr>
      <td>Cardiac catheterization</td>
      <td>Congenital heart disease, valve and shunt assessment, CAD</td>
      <td>Direct measurement, enables interventions</td>
      <td>Invasive, radiation and contrast exposure</td>
    </tr>
    <tr>
      <td>Coronary CT angiography</td>
      <td>Coronary artery and congenital anatomy</td>
      <td>Noninvasive, high-resolution anatomy</td>
      <td>Radiation, improved with slower heart rate</td>
    </tr>
    <tr>
      <td>CMR imaging</td>
      <td>Congenital disease, myocarditis, amyloidosis, hypertrophic cardiomyopathy, RV cardiomyopathy</td>
      <td>High-resolution, no radiation, 3D reconstruction</td>
      <td>Availability, contraindicated in some implants or CKD, claustrophobia</td>
    </tr>
    <tr>
      <td>Chest CT with contrast</td>
      <td>Aortic disease, cardiac masses, pericardial disease</td>
      <td>High-resolution, 3D vascular anatomy</td>
      <td>Radiation and contrast exposure</td>
    </tr>
    <tr>
      <td>99m-Technetium pyrophosphate scintigraphy</td>
      <td>ATTR cardiac amyloidosis</td>
      <td>High specificity for ATTR</td>
      <td>Radiation exposure</td>
    </tr>
  </tbody>
</table>
<p>
  ARVC = arrhythmogenic right ventricular cardiomyopathy; ASD = atrial septal defect; ATTR = amyloid transthyretin; CKD = chronic kidney disease; CMR = cardiac magnetic resonance; EF = ejection fraction; ICD = implantable cardioverter-defibrillator; LV = left ventricular; LVEF = left ventricular ejection fraction; MUGA = multigated acquisition; RV = right ventricular.
</p>
<p>
  <em>*Group I gadolinium-based contrast agents are contraindicated in patients with end-stage kidney disease or an estimated glomerular filtration rate &lt; 30 mL/min/1.73 m<sup>2</sup>. Group II gadolinium-based contrast agents are not contraindicated in patients with CKD. Data are insufficient to make a recommendation for Group III gadolinium-based contrast agents in CKD.</em>
</p>


---

### üñºÔ∏è Supplemental Figures

<figure>
  <img src="tee_negative_laa_thrombus.jpg" alt="TEE showing no thrombus in LAA" style="max-width: 100%; height: auto;">
  <figcaption><strong>Figure 1:</strong> Transesophageal echocardiogram showing the left atrium (LA) and left atrial appendage (LAA) with no thrombus present. The transducer is posterior to the heart, enhancing LAA visualization.</figcaption>
</figure>

<figure>
  <img src="99mtcpyp_attr_amyloidosis.jpg" alt="99mTc-PYP scan in ATTR cardiac amyloidosis" style="max-width: 100%; height: auto;">
  <figcaption><strong>Figure 2:</strong> 99m-Technetium pyrophosphate (99mTc-PYP) scan demonstrating cardiac uptake greater than bone uptake in a patient with hereditary transthyretin (ATTR) amyloidosis at both 1 hour and 3 hours.</figcaption>
</figure>